Truist Financial Reiterates Buy Rating for Exelixis (NASDAQ:EXEL)
Truist Financial reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note released on Monday morning,Benzinga reports. They currently have a $55.00 price objective on the biotechnology company’s stock, up from their previous price objective of $43.00. EXEL has been the topic of several other research reports. UBS Group […]
Truist Financial reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note released on Monday morning,Benzinga reports. They currently have a $55.00 price objective on the biotechnology company’s stock, up from their previous price objective of $43.00. EXEL has been the topic of several other research reports. UBS Group […]
